Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.61 |
| ▸ | LMNA | P02545 | 5/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.51 |
| ▸ | PGR | P06401 | 1/20 | 0.51 |
| ▸ | SLC12A2 | P55011 | 1/20 | 0.49 |
| ▸ | SLC12A5 | Q9H2X9 | 1/20 | 0.49 |
| ▸ | FABP4 | P15090 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5891884 | 0.82 | SMN1; SMN2 (0.56) | SMN1; SMN2LMNAMAPTALDH1A1HTT | |
| SCHEMBL28195553 | 0.81 | HTT (0.75) | SMN1; SMN2LMNAMAPTMAPK1ALDH1A1 | |
| SCHEMBL4454443 | 0.78 | NSD2 (0.72) | SMN1; SMN2LMNAMAPTFABP4 | |
| Hydrochloric Acid SCHEMBL4447200 | 0.77 | NSD2 (0.73) | SMN1; SMN2LMNAMAPTFABP4 | |
| SCHEMBL13074347 | 0.77 | SMN1; SMN2 (0.85) | SMN1; SMN2LMNAMAPTALDH1A1HTT | |
| SCHEMBL7271170 | 0.75 | SMN1; SMN2 (0.68) | SMN1; SMN2LMNAMAPTALDH1A1HTT | |
| SCHEMBL9210947 | 0.75 | SMN1; SMN2 (0.50) | SMN1; SMN2LMNAMAPTMAPK1ALDH1A1 | |
| SCHEMBL16135581 | 0.74 | SMN1; SMN2 (0.48) | SMN1; SMN2LMNAMAPTMAPK1ALDH1A1 | |
| SCHEMBL17235938 | 0.74 | MAPK1 (0.65) | SMN1; SMN2LMNAMAPTMAPK1ALDH1A1 | |
| SCHEMBL7257961 | 0.74 | SMN1; SMN2 (0.66) | SMN1; SMN2LMNAMAPTALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120270902-A1 | N-substituted benzene sulfonamides | ELAN PHARMACEUTICALS, INC. (US) | 2012-10-25 | — | — | US | disclosed |
| US-8193389-B2 | N-substituted benzene sulfonamides | ELAN PHARMACEUTICALS, INC. (US) | 2012-06-05 | — | — | US | disclosed |
| US-20050245573-A1 | N-substituted benzene sulfonamides | ELAN PHARMACEUTICALS, INC. | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245573-A1 | N-substituted benzene sulfonamides | PSEN1, PSEN2, BCHE | SMN1; SMN2 148/4885LMNA 3051/4885MAPT 106/4885 |
| US-20120270902-A1 | N-substituted benzene sulfonamides | PSEN1, PSEN2, BCHE | SMN1; SMN2 148/4885LMNA 3051/4885MAPT 106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.